N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1997-08, Vol.40 (17), p.2674-2687
Hauptverfasser: Elworthy, Todd R, Ford, Anthony P. D. W, Bantle, Gary W, Morgans, David J, Ozer, Rachel S, Palmer, Wylie S, Repke, David B, Romero, Magarita, Sandoval, Leticia, Sjogren, Eric B, Talamás, Francisco X, Vazquez, Alfredo, Wu, Helen, Arredondo, Nicolas F, Blue, David R, DeSousa, Andrea, Gross, Lisa M, Kava, M. Shannon, Lesnick, John D, Vimont, Rachel L, Williams, Timothy J, Zhu, Quan-Ming, Pfister, Jürg R, Clarke, David E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2687
container_issue 17
container_start_page 2674
container_title Journal of medicinal chemistry
container_volume 40
creator Elworthy, Todd R
Ford, Anthony P. D. W
Bantle, Gary W
Morgans, David J
Ozer, Rachel S
Palmer, Wylie S
Repke, David B
Romero, Magarita
Sandoval, Leticia
Sjogren, Eric B
Talamás, Francisco X
Vazquez, Alfredo
Wu, Helen
Arredondo, Nicolas F
Blue, David R
DeSousa, Andrea
Gross, Lisa M
Kava, M. Shannon
Lesnick, John D
Vimont, Rachel L
Williams, Timothy J
Zhu, Quan-Ming
Pfister, Jürg R
Clarke, David E
description Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values:  8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.
doi_str_mv 10.1021/jm970166j
format Article
fullrecord <record><control><sourceid>acs_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_2782102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>c664341131</sourcerecordid><originalsourceid>FETCH-LOGICAL-a167t-299a98318c95cc7202ec42fbc6ac45c04b64c4295b49ba2b748ff0d88fd8fa483</originalsourceid><addsrcrecordid>eNo9UUFOwzAQtBBIlMKBH-QAR4PtOIlzjAptkaoCoj1bG8dBDmkc2WlF4cIz-AYf4RG8hFRFnFaanRnt7CB0TskVJYxeV6s0ITSOqwM0oBEjmAvCD9GAEMYwi1l4jE68rwghIWXhAL3Pcea2dWta7eDNNNsaz38-PnHrbLutYWUaG9xoZzbQmY32gS2Dqe60s9Crgmxlih4EH4zXjeqMbaAOls56XWu1EwTfXxRnhdONVbrtrAuypoNn2xjf-VN0VELt9dnfHKLl-HYxmuLZ_eRulM0w0DjpMEtTSEVIhUojpRJGmFaclbmKQfFIEZ7HvAfSKOdpDixPuChLUghRFqIELsIhutj7tuAV1KWDRhkvW2dWfQrJEsH63_U0vKf1t-nX_zW4FxknYRLJxcOTnIxF_DhNF3Jne7nng_KysmvXh_eSErkrQv4XEf4CCAB-YQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</title><source>American Chemical Society Journals</source><creator>Elworthy, Todd R ; Ford, Anthony P. D. W ; Bantle, Gary W ; Morgans, David J ; Ozer, Rachel S ; Palmer, Wylie S ; Repke, David B ; Romero, Magarita ; Sandoval, Leticia ; Sjogren, Eric B ; Talamás, Francisco X ; Vazquez, Alfredo ; Wu, Helen ; Arredondo, Nicolas F ; Blue, David R ; DeSousa, Andrea ; Gross, Lisa M ; Kava, M. Shannon ; Lesnick, John D ; Vimont, Rachel L ; Williams, Timothy J ; Zhu, Quan-Ming ; Pfister, Jürg R ; Clarke, David E</creator><creatorcontrib>Elworthy, Todd R ; Ford, Anthony P. D. W ; Bantle, Gary W ; Morgans, David J ; Ozer, Rachel S ; Palmer, Wylie S ; Repke, David B ; Romero, Magarita ; Sandoval, Leticia ; Sjogren, Eric B ; Talamás, Francisco X ; Vazquez, Alfredo ; Wu, Helen ; Arredondo, Nicolas F ; Blue, David R ; DeSousa, Andrea ; Gross, Lisa M ; Kava, M. Shannon ; Lesnick, John D ; Vimont, Rachel L ; Williams, Timothy J ; Zhu, Quan-Ming ; Pfister, Jürg R ; Clarke, David E</creatorcontrib><description>Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values:  8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm970166j</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Biological and medical sciences ; Medical sciences ; Pharmacology. Drug treatments ; Urinary system</subject><ispartof>Journal of medicinal chemistry, 1997-08, Vol.40 (17), p.2674-2687</ispartof><rights>Copyright © 1997 American Chemical Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm970166j$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm970166j$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2782102$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Elworthy, Todd R</creatorcontrib><creatorcontrib>Ford, Anthony P. D. W</creatorcontrib><creatorcontrib>Bantle, Gary W</creatorcontrib><creatorcontrib>Morgans, David J</creatorcontrib><creatorcontrib>Ozer, Rachel S</creatorcontrib><creatorcontrib>Palmer, Wylie S</creatorcontrib><creatorcontrib>Repke, David B</creatorcontrib><creatorcontrib>Romero, Magarita</creatorcontrib><creatorcontrib>Sandoval, Leticia</creatorcontrib><creatorcontrib>Sjogren, Eric B</creatorcontrib><creatorcontrib>Talamás, Francisco X</creatorcontrib><creatorcontrib>Vazquez, Alfredo</creatorcontrib><creatorcontrib>Wu, Helen</creatorcontrib><creatorcontrib>Arredondo, Nicolas F</creatorcontrib><creatorcontrib>Blue, David R</creatorcontrib><creatorcontrib>DeSousa, Andrea</creatorcontrib><creatorcontrib>Gross, Lisa M</creatorcontrib><creatorcontrib>Kava, M. Shannon</creatorcontrib><creatorcontrib>Lesnick, John D</creatorcontrib><creatorcontrib>Vimont, Rachel L</creatorcontrib><creatorcontrib>Williams, Timothy J</creatorcontrib><creatorcontrib>Zhu, Quan-Ming</creatorcontrib><creatorcontrib>Pfister, Jürg R</creatorcontrib><creatorcontrib>Clarke, David E</creatorcontrib><title>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values:  8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.</description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Urinary system</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNo9UUFOwzAQtBBIlMKBH-QAR4PtOIlzjAptkaoCoj1bG8dBDmkc2WlF4cIz-AYf4RG8hFRFnFaanRnt7CB0TskVJYxeV6s0ITSOqwM0oBEjmAvCD9GAEMYwi1l4jE68rwghIWXhAL3Pcea2dWta7eDNNNsaz38-PnHrbLutYWUaG9xoZzbQmY32gS2Dqe60s9Crgmxlih4EH4zXjeqMbaAOls56XWu1EwTfXxRnhdONVbrtrAuypoNn2xjf-VN0VELt9dnfHKLl-HYxmuLZ_eRulM0w0DjpMEtTSEVIhUojpRJGmFaclbmKQfFIEZ7HvAfSKOdpDixPuChLUghRFqIELsIhutj7tuAV1KWDRhkvW2dWfQrJEsH63_U0vKf1t-nX_zW4FxknYRLJxcOTnIxF_DhNF3Jne7nng_KysmvXh_eSErkrQv4XEf4CCAB-YQ</recordid><startdate>19970815</startdate><enddate>19970815</enddate><creator>Elworthy, Todd R</creator><creator>Ford, Anthony P. D. W</creator><creator>Bantle, Gary W</creator><creator>Morgans, David J</creator><creator>Ozer, Rachel S</creator><creator>Palmer, Wylie S</creator><creator>Repke, David B</creator><creator>Romero, Magarita</creator><creator>Sandoval, Leticia</creator><creator>Sjogren, Eric B</creator><creator>Talamás, Francisco X</creator><creator>Vazquez, Alfredo</creator><creator>Wu, Helen</creator><creator>Arredondo, Nicolas F</creator><creator>Blue, David R</creator><creator>DeSousa, Andrea</creator><creator>Gross, Lisa M</creator><creator>Kava, M. Shannon</creator><creator>Lesnick, John D</creator><creator>Vimont, Rachel L</creator><creator>Williams, Timothy J</creator><creator>Zhu, Quan-Ming</creator><creator>Pfister, Jürg R</creator><creator>Clarke, David E</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope></search><sort><creationdate>19970815</creationdate><title>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</title><author>Elworthy, Todd R ; Ford, Anthony P. D. W ; Bantle, Gary W ; Morgans, David J ; Ozer, Rachel S ; Palmer, Wylie S ; Repke, David B ; Romero, Magarita ; Sandoval, Leticia ; Sjogren, Eric B ; Talamás, Francisco X ; Vazquez, Alfredo ; Wu, Helen ; Arredondo, Nicolas F ; Blue, David R ; DeSousa, Andrea ; Gross, Lisa M ; Kava, M. Shannon ; Lesnick, John D ; Vimont, Rachel L ; Williams, Timothy J ; Zhu, Quan-Ming ; Pfister, Jürg R ; Clarke, David E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a167t-299a98318c95cc7202ec42fbc6ac45c04b64c4295b49ba2b748ff0d88fd8fa483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elworthy, Todd R</creatorcontrib><creatorcontrib>Ford, Anthony P. D. W</creatorcontrib><creatorcontrib>Bantle, Gary W</creatorcontrib><creatorcontrib>Morgans, David J</creatorcontrib><creatorcontrib>Ozer, Rachel S</creatorcontrib><creatorcontrib>Palmer, Wylie S</creatorcontrib><creatorcontrib>Repke, David B</creatorcontrib><creatorcontrib>Romero, Magarita</creatorcontrib><creatorcontrib>Sandoval, Leticia</creatorcontrib><creatorcontrib>Sjogren, Eric B</creatorcontrib><creatorcontrib>Talamás, Francisco X</creatorcontrib><creatorcontrib>Vazquez, Alfredo</creatorcontrib><creatorcontrib>Wu, Helen</creatorcontrib><creatorcontrib>Arredondo, Nicolas F</creatorcontrib><creatorcontrib>Blue, David R</creatorcontrib><creatorcontrib>DeSousa, Andrea</creatorcontrib><creatorcontrib>Gross, Lisa M</creatorcontrib><creatorcontrib>Kava, M. Shannon</creatorcontrib><creatorcontrib>Lesnick, John D</creatorcontrib><creatorcontrib>Vimont, Rachel L</creatorcontrib><creatorcontrib>Williams, Timothy J</creatorcontrib><creatorcontrib>Zhu, Quan-Ming</creatorcontrib><creatorcontrib>Pfister, Jürg R</creatorcontrib><creatorcontrib>Clarke, David E</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elworthy, Todd R</au><au>Ford, Anthony P. D. W</au><au>Bantle, Gary W</au><au>Morgans, David J</au><au>Ozer, Rachel S</au><au>Palmer, Wylie S</au><au>Repke, David B</au><au>Romero, Magarita</au><au>Sandoval, Leticia</au><au>Sjogren, Eric B</au><au>Talamás, Francisco X</au><au>Vazquez, Alfredo</au><au>Wu, Helen</au><au>Arredondo, Nicolas F</au><au>Blue, David R</au><au>DeSousa, Andrea</au><au>Gross, Lisa M</au><au>Kava, M. Shannon</au><au>Lesnick, John D</au><au>Vimont, Rachel L</au><au>Williams, Timothy J</au><au>Zhu, Quan-Ming</au><au>Pfister, Jürg R</au><au>Clarke, David E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1997-08-15</date><risdate>1997</risdate><volume>40</volume><issue>17</issue><spage>2674</spage><epage>2687</epage><pages>2674-2687</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a “negative screen” for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure−affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA 2 values:  8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2−3 orders of magnitude selectivity over the α1D-AR.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><doi>10.1021/jm970166j</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1997-08, Vol.40 (17), p.2674-2687
issn 0022-2623
1520-4804
language eng
recordid cdi_pascalfrancis_primary_2782102
source American Chemical Society Journals
subjects Biological and medical sciences
Medical sciences
Pharmacology. Drug treatments
Urinary system
title N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A06%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=N-Arylpiperazinyl-N%E2%80%98-propylamino%20Derivatives%20of%20Heteroaryl%20Amides%20as%20Functional%20Uroselective%20%CE%B11-Adrenoceptor%20Antagonists&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Elworthy,%20Todd%20R&rft.date=1997-08-15&rft.volume=40&rft.issue=17&rft.spage=2674&rft.epage=2687&rft.pages=2674-2687&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm970166j&rft_dat=%3Cacs_pasca%3Ec664341131%3C/acs_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true